Vitronectin

被引:359
作者
Schvartz, I [1 ]
Seger, D [1 ]
Shaltiel, S [1 ]
机构
[1] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel
关键词
plasminogen activator inhibitor-1; cell adhesion; integrins; fibrinolysis;
D O I
10.1016/S1357-2725(99)00005-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Vitronectin is a multifunctional glycoprotein present in blood and in the extracellular matrix. It binds glycosaminoglycans, collagen, plasminogen and the urokinase-receptor. and also stabilizes the inhibitory conformation or plasminogen activation inhibitor-1. By its localization in the extracellular matrix and its binding to plasminogen activation inhibitor-1, vitronectin can potentially regulate the proteolytic degradation of this matrix. In addition, vitronectin binds to complement, to heparin and to thrombin-antithrombin III complexes, implicating its participation in the immune response and in the regulation of clot formation. The biological functions of vitronectin can be modulated by proteolytic enzymes, and by exo- and ecto-protein kinases present in blood. Vitronectin contains an RGD sequence, through which it binds to the integrin receptor alpha(v)beta(3), and is involved in the cell attachment, spreading and migration. Antibodies against alpha(v)beta(3) or synthetic peptides containing an RGD sequence are now being tested as therapeutic agents in the treatment of human cancers, bone diseases (e.g, osteoporosis) and in pathological disorders which involve angiogenesis. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:539 / 544
页数:6
相关论文
共 15 条
[1]
Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells [J].
Bafetti, LM ;
Young, TN ;
Itoh, Y ;
Stack, MS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (01) :143-149
[2]
The cluster of basic amino acids in vitronectin contributes to its binding of plasminogen activator inhibitor-1: Evidence from thrombin-, elastase- and plasmin-cleaved vitronectins and anti-peptide antibodies [J].
Gechtman, Z ;
Belleli, A ;
Lechpammer, S ;
Shaltiel, S .
BIOCHEMICAL JOURNAL, 1997, 325 :339-349
[3]
Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization [J].
Hammes, HP ;
Brownlee, M ;
Jonczyk, A ;
Sutter, A ;
Preissner, KT .
NATURE MEDICINE, 1996, 2 (05) :529-533
[4]
HESS S, 1995, THROMB HAEMOSTASIS, V74, P258
[5]
Huang XZ, 1998, J CELL SCI, V111, P2189
[6]
KOST C, 1992, J BIOL CHEM, V267, P12098
[7]
The regulation of growth and intracellular signaling by integrins [J].
Meredith, JE ;
Winitz, S ;
Lewis, JM ;
Hess, S ;
Ren, XD ;
Renshaw, MW ;
Schwartz, MA .
ENDOCRINE REVIEWS, 1996, 17 (03) :207-220
[8]
Preissner KT, 1997, THROMB HAEMOSTASIS, V78, P88
[9]
Phosphorylation of vitronectin by casein kinase II - Identification of the sites and their promotion of cell adhesion and spreading [J].
Seger, D ;
Gechtman, Z ;
Shaltiel, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (38) :24805-24813
[10]
Seiffert D, 1997, HISTOL HISTOPATHOL, V12, P787